Purchase this article with an account.
Catherine Meyerle, Jay Chhablani, Igor Kozak, Francesco Pichi, Maria H Berrocal, Rishi P Singh, Lihteh Wu, Antonio M B Casella, Ahmad M Mansour, Fernando Arevalo, ; OUTCOMES OF TREATMENT OF CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH CENTRAL SEROUS CHORIORETINOPATHY WITH INTRAVITREAL ANTIANGIOGENIC AGENTS. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3725.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report clinical characteristics and treatment outcomes from the largest case series to date of choroidal neovascularization (CNV) secondary to central serous chorioretinopathy (CSC).
Retrospective multicenter analysis of 46 eyes of 43 consecutive subjects with CNV associated with CSC was conducted. Collected data included demographic information; history of presenting illness; visual acuity; imaging results and treatment details. Main outcome measures were the proportion of eyes that had improved visual acuity (3 or more lines), stable acuity (within ±1 line), or decreased acuity (3 or more lines) at the final visit as compared with baseline examination. Secondary efficacy outcomes included change in visual acuity at final follow up, number of injections, treatment free interval, and adverse events.
Mean age was 57.56 years (range 29-79 years). Thirty of the subjects were men and 13 were female. Mean follow up duration was 38.3±58.9 months. Classic CNV was present in 21 eyes (46%), minimally classic in 6 eyes (13%) and occult in 19 eyes (41%). Type 1 CNV occured in 20 eyes (44%), type 2 CNV was present in 25 eyes (54%) and type 3 CNV (2%) was reported for one eye. Thirty-four eyes received intravitreal bevacizumab and 12 received ranibizumab. Eight of these eyes also received aflibercept. More than 3 lines of visual acuity improvement occurred in 12 (26%) eyes, vision was stable (within ±1 line) in 19 (41%) eyes, and more than 3 lines of visual loss was noted in 6 (13%) eyes. Mean change in number of lines was 1.16±3.74. Mean number of anti-vascular endothelial growth factor (VEGF) injections during the follow up was 4.45±4.1. The longest treatment free interval was 8.9±7.5 months. The median treatment free interval was 7.8 months. No systemic or ocular serious adverse events were noted.
Anti-VEGF intravitreal injections as a primary treatment for CNV secondary to CSC in this large case series was safe and efficacious, without any serious systemic or ocular adverse events.
This PDF is available to Subscribers Only